Endothelial progenitor cells: Pathogenetic role and therapeutic perspectives

Journal of Nephrology

Volumn 22, Issue 4, 2009, Pages 463-475

  Allegra, Alessandro ^a   Coppolino, Giuseppe ^a   Bolignano, Davide ^a   Giacobbe, Maria Stella ^a   Alonci, Andrea ^a   D'Angelo, Arianna ^a   Bellomo, Giacomo ^a   Teti, Diana ^a   Loddo, Saverio ^a   Musolino, Caterina ^a   Buemi, Michele ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Circulating endothelial cells; Neovascularization; Restenosis; Tissue repair

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

ANEMIA; CARDIOVASCULAR DISEASE; CD34 SELECTION; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEMATOPOIETIC CELL; HUMAN; HYPERTENSION; ISCHEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PREGNANCY; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; TISSUE REPAIR; TUMOR GROWTH; ANIMAL; BONE NECROSIS; CYTOLOGY; NEOPLASM; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; KIDNEY FAILURE; NEOPLASMS; OSTEONECROSIS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 70249087711     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Caplan BA, Schwartz CJ. Increased endothelial cell turnover in areas of in vivo Evans blue uptake in the pig aorta. Atherosclerosis. 1973;17:401-417.
2. Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis. J Mol Med. 2004;82:671-677.
3. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med. 2004;4:498-508.
4. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
5. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-1992.
6. Vasa M, Fichtlscherer S, Aicher A. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-E7.
7. Bahlmann FH, deGroot KD, Mueller O, Hertel B, Haller H, Flisser D. Stimulation of endothelial progenitor cells. A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45:526-529.
8. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2004;18:203-209.
9. Coppolino G, Bolignano D, Campo S, et al. Circulating progenitor cells after cold pressor test in hypertensive and uremic patients. Hypertens Res. 2008;31:717-724.
10. Valgimigli M, Rigolin GM, Fucili A. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation. 2004;110:1209-1212.
11. Ghani U, Shuaib A, Salam A. Endothelial progenitor cells during cerebrovascular disease. Stroke. 2005;36:151-153.
12. Simper D, Wang S, Deb A. Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of non cardiac origin are enriched in transplant atherosclerosis. Circulation. 2003;107:143-149.
13. Foresta C, Caretta N, Lana A, Cabrelle A, Palu G, Ferlin A. Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res. 2005;17:288-290.
14. Shintani S, Murohara T, Ikeda H. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776-2779.
15. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111:2981-2987.
16. Wermer N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Eng J Med. 2005;353:999-1007.
17. Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation. 2003;108:3122-3127.
18. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
19. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
20. Scheubel RJ, Zorn H, Rolf-Edgar S. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol. 2003;42:2073-2080.
21. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res. 2002;90:e89-e93.
22. Rivard A, Berthou-Soulie L, Principe N. Age dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J Biol Chem. 2000;275:29643-29647.
23. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation. 2002;105:2133-2135.
24. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
25. Pellegatta F, Bragheri M, Grigore L. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. Int J Mol Med. 2006;17:203-208.
26. Assmus B, Urbich C, Aicher A. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92:1049-1055.
27. Llevadot J, Murasawa S, Kureishi Y. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
28. Dimmeler S, Aicher A, Vasa M. HMG-CoA reductase inhibitors (statins increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
29. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003;108:457-463.
30. Kondo T, Hayashi M, Takeshita K, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol. 2004;24:1442-1447.
31. Wang X, Zhu J, Chen J, Shang Y. Effects of nicotine on the number and activity of circulating endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol. 2004;36:233-239.
32. Wang X, Zhu J, Chen J, Shang Y. Effects of nicotine on the number and activity of circulating endothelial progenitor cells. J Clin Pharmacol. 2004;44:881-889.
33. Chen JZ, Zhu JH, Wang XX. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol. 2004;36:233-239.
34. Laufs U, Werner N, Link A. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004;109:220-226.
35. Rehman J, Li J, Parvathaneni L. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol. 2004;43:2314-2318.
36. Sandri M, Adams V, Gielen S. Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation. 2005;111:3391-3399.
37. Werner N, Nickening G. Clinical and therapeutical implications of EPC biology in atherosclerosis. J Cell Mol Med. 2006;2:318-332.
38. Coppolino G, Basile G, Bolignano D, Nicita-Mauro V, Buemi M. Circulating endothelial progenitor cell mobilization in centenarians: a powerful source for extended renal life. J Am Geriatr Soc. 2007;55:1693-1694.
39. Loomans CJ, de Koening EJ, Staal FJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type I diabetes. Diabetes. 2004;63:195-199.
40. Tepper OM, Galiano RD, Capla JM. Human endothelial progenitor cells from type II diabetes exhibit impairment proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781-2786.
41. Fadini GP, Miorin MM, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45:1449-1457.
42. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Atherosclerosis Thromb Vasc Biol. 2006;26:2140-2146.
43. Krankel N, Adams V, Linke A, et al. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol. 2005;25:698-703.
44. Fadini GP, Pucci L, Baesso I, et al. Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia. 2007;50:2156-2163.
45. Fadini GP, de Kreutzenberg SV, Coracina A, et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J. 2006;27:2247-2255.
46. Pistrosch F, Herbrig K, Oelschlaegel U. PPPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 2005;183:163-167.
47. Choi JH, Kim KL, Huh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004;24:1246-1252.
48. Herbrig K, Pistrosch F, Foerster S, Gross P. Endothelial progenitor cells in chronic renal insufficiency. Kidney Blood Press Res. 2006;29:34-31.
49. Miyazaki H, Matsuoka H, Itabe H, et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation. 2000;101:1002-1006.
50. Kosch M, Levers A, Fobker M, et al. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress. Nephrol Dial Transplant. 2003;18:1370-1375.
51. Sturiale A, Coppolino G, Loddo S, et al. Effects of haemodialysis on circulating endothelial progenitor cell count. Blood Purif. 2007;25:242-251.
52. de Groot K, Bahlmann FH, Sowa J, et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int. 2004;66:641-646.
53. Herbrig K, Pistrosch F, Oelschlaegel U, et al. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis. 2004;44:840-849.
54. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol. 1 2005;46(9): 1693-1701.
55. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9:1370-1376.
56. Aicher A, Heeschen C, Dimmeler S. The role of NOS3 in stress cell mobilization. Trends Mol Med. 2004;9:421-425.
57. Parfrey PS. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606-1615.
58. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. 2003;(85):S105-S110.
59. Zoccali C, Mallamaci F, Tripepi GS, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:134-141.
60. Buemi M, Aloisi E, Coppolino G, et al. The effect of two different protocols of potassium haemodiafiltration on QT dispersion. Nephrol Dial Transplant. 2005;20:1148-1154.
61. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine- induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438.
62. Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int. 2003;(84):S50-S53.
63. Westerweel PE, Hoefer IE, Blankestijn PJ, et al. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol. 2007;292:F1132-F1140.
64. Rookmaaker MB, Smits AM, Tolboom H, et al. Bone-marrow-derived cells contributes to glomerular endothelial repair in experimental glomerulonephritis. Am J Pathol. 2003;87:553-562.
65. Rookmaaker MB, Tolboom H, Goldschmeding R, Zwaginga JJ, Rabelink TJ, Verhaar MC. Bone-marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy. Blood. 2002;99:1095.
66. Cornacchia F, Fornoni A, Plati AR, et al. Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors. J Clin Invest. 2001;108:1649-1656.
67. Nastro E, Musolino C, Allegra A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol. 2006;117:181-187.
68. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
69. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253-4254.
70. Carter GD, Gross AN. Bisphosphonates and avascular necrosis of the jaw. Aust Dent J. 2003;48:268.
71. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg. 2004;62:763-764.
72. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003;61:1238-1239.
73. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology. 2006;20:1053-1062.
74. Hellstein JW, Marek BS. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63:682-689.
75. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538-6544.
76. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055-1061.
77. Wood J, Schnell C, Green JR. Zoledronic acid, a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model [abstract]. Proc Am Soc Clin Oncol 2000;9:664.
78. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2002;8:1080-1084.
79. Vincenzi B, Santini D, Rocci L, Tonini G. Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol. 2003;14:806-807.
80. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69:35-43.
81. Allegra A, Oteri G, Nastro E, et al. Patients with bisphosphonate-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol. 2007;25:164-169.
82. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972.
83. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85:221-228.
84. Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation. 2003;107:3059-3065.
85. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003;108:3115-3121.
86. Gussin HAE, Bischoff FZ, Hoffman R, Elias S. Endothelial precursor cells in the peripheral blood of pregnant women. J Soc Gynecol Investig. 2002;9:357-361.
87. Sugawara J, Mitsui-Saito M, Hoshiai T, Habayashi C, Rimura Y, Kunihiro O. Circulating endothelial progenitor cells during human pregnancy. J Clin Endocrinol Metab. 2005;90:1845-1848.
88. Buemi M, Allegra A, D'Anna R, et al. Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol. 2007;196:e1-e6.
89. Paarlberg KM, Vingerhoets AJ, Passchier J. Psychosocial predictors of low birthweight: a prospective study. Br J Obstet Gynaecol. 1999;106:834-841.
90. Buemi M, Bolignano D, Barilla A, et al. Preeclampsia and cardiovascular risk: general characteristics, counseling and follow-up. J Nephrol. In press.
91. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc. 2006;3:680-686.
92. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106:1311-1319.
93. Tang K, Rossiter HB, Wagner PD, Breen EC. Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice. J Appl Physiol. 2004;97:1559-1566.
94. Aoshiba K, Nagai A. Differences in airway remodeling between asthma and chronic obstructive pulmonary disease. Clin Rev Allergy Immunol. 2004;27:35-43.
95. Henson MP, Vandivier RW, Douglas IS. Cell death, remodeling, and repair in chronic obstructive pulmonary disease? Proc Am Thorac Soc. 2006;3:713-717.
96. Zokazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol. 2006;18:1-9.
97. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9:702-712.
98. Lyden D, Hattory K, Dias S. Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201.
99. De Bont ES, Guikema JE, Scerpen F. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. Cancer Res. 2001;61:7654-7659.
100. Beerepoot LV, Mehra N, Vermmat JSP, Zonnbenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol. 2004;15:139-145.
101. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
102. Ruzinova MB. Effect of angiogenesis inhibition by Id loss and the contribution of bone marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell. 2003;4:277-289.
103. Jain RK, Duda DG. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell. 2003;3:515-516.
104. Wierzbowska A, Robak T, Krawczynska A, et al. Circulating endothelial cells in patients with acute myeloid leukaemia. Eur J Haematol. 2005;75:492-497.
105. Liesveld JL, Rosell KE, Lu C, et al. Acute myelogenous leukaemia-microenvironment interactions: role of endothelial cells and proteasome inhibition. Hematology. 2005;10:483-494.
106. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105:3286-3294.
107. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood. 2006;107:2531-2535.
108. Gunsilius E. Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Adv Exp Med Biol. 2003;522:17-24.
109. Streubel B, Chott A, Huber D. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004;351:250-259.
110. Kawamoto A. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103:634-637.
111. Ott I. Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. FASEB J. 2005;19:992-994.
112. Otani A. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med. 2002;8:1004-1010.
113. Hattori K. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193:1005-1014.
114. Taguchi A. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004;114:330-338.
115. Religa P. Smooth-muscle progenitor cells of bone marrow origin contribute to the development of neointimal thickenings in rat aortic allografts and injured rat carotid arteries. Transplantation. 2002;74:1310-1315.
116. Priller J. Neogenesis of cerebellar Purkinje neurons from gene-marked bone marrow cells in vivo. J Cell Biol. 2001;155:733-738.
117. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell. 2002;111:589-601.
118. Torrente Y. Human circulating AC133+ stem cells restore dystrophin expression and meliorate function in dystrophic skeletal muscle. J Clin Invest. 2004;114:182-195.
119. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest. 2004;113:243-252.
120. Phillips RJ. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114:438-446.
121. Schachinger V, Assmus B, Britten MB. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J Am Coll Cardiol. 2004;44:1690-1699.
122. Tateishi-Yuyama E, Matsubara H, Murohara T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427-435.
123. Kaushal S, Amiel GE, Guleserian KJ. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med. 2001;7:1035-1040.
124. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol. 2007;49:741-752.
125. Bahlmann FH, De Groot K, Spandau JM. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103:921-926.
126. Bahlmann FH, De Groot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64:1648-1652.
127. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a Pl 3-kinase-dependent manner. Cardiovasc Res. 2005;68:299-306.
128. Lipsic E, van der Voors AA, Westenbrink BD, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20:135-141.
129. Cho HJ, Kim HS, Lee MM, et al. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation. 2003;108:2918-2925.
130. Tamarat R, Silvestre JS, Ricousse-Roussanne S, Barateau V, Lecomte-Raclet L, Clergue M. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol. 2004;164:457-466.
131. Iwaguro H, Yamaguchi J, Kalka C. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 2002;105:732-738.
132. Murasawa S, Llevadot J, Silver M, Isner JM, Losordo DW, Asahara T. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation. 2002;106:1133-1139.
133. Kong D, Melo LG, Gnecchi M, et al. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation. 2004;110:2039-2046.
134. Forte A, Cipollaro M, Cascino A, Galderisi U. Pathophysiology of stem cells in restenosis. Histol Histopathol. 2007;22:547-557.
135. Shirota T, Yasui H, Shimokawa H, Matsuda T. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials. 2003;24:2295-2302.
136. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cells capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol. 2005;45:1574-1579.
137. Blindt R, Vogt F, Astafieva I, et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol. 2006;47:1786-1795.
138. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation. 2005;111:926-931.